GENE ONLINE|News &
Opinion
Blog

2022-06-27| In-DepthSpecial

Roe Reversal May Cause Downstream Issues in Repurposing Mifepristone

by Reed Slater
Share To

The Supreme Court of the United State’s decision to end the constitutional right to abortions (Roe v. Wade) has garnered attention for one of America’s most common abortion-inducing drugs, mifepristone. The drug, originally FDA approved in 2000 for use inducing pregnancy termination, has shown promise in other treatment areas like cancer, hormonal diseases, and mental health disorders. However, because individual states determine abortion laws now, access to mifepristone may be restricted for research purposes even outside of pregnancy termination. 

 

Mifepristone’s Current Uses and Mechanisms of Action

 

The FDA approved mifepristone for two indications: early pregnancy termination in conjunction with misoprostol and the second came in 2012 to treat Cushing’s syndrome. 

It's free! Log in now to read

LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top